my account  log out
 

Setipiprant

Create: 07/11/2019
Expired Date:12/31/2019
Category: Drugs&Pharmaceutical [Health&Medical&Pharmaceutical]
Message:Setipiprant (ACT-129,968, KYTH-105) is a drug acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application. Web: www.rawsgear.com Web: www.rawsgearpharma.com Email: gear@quality-steroid.com Skype: +8615711952876 Whatsapp +8615711952876
City:Wuhan Hubei[CN] 
Location:
 
Jul 11 2019Clonidine hydrochloride376
Jul 11 2019Phenacetin355
Jul 11 2019CRL-40,940355
Jul 11 2019Pregabalin (4-Methylpregabalin)348
Jul 11 2019Phenylacetonitrile336
Jul 11 2019DMBA (1,3-Dimethylbutylamine hydrochloride)347
Jul 11 2019DMHA (1,5-dimethyl-hexylamin)358
Jul 11 2019DMAA (1,3-Dimethylamylamine)347
Jul 11 2019Setipiprant350
Jul 11 20191,3-dimethyl-butylamine citrate362

return back

Copyright © toextrade Inc. All rights reserved. Contact us